24 August 2023 
EMA/334883/2023 
Shortage of Tresiba (insulin degludec) 
pre
filled pens (100 and 200 units/ml) 
Indication 
‑
Tresiba is used to treat type 1 and type 2 diabetes in adults 
and children aged 1 to 18 years of age. 
Reason for shortage  
There has been a delay in the production of Tresiba at some of 
the company’s sites. This has led to intermittent supply 
shortages for Tresiba that are expected to continue until the 
end of 2023 in some EU Member States.  
Member States affected1 
Austria, Belgium, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, Netherlands, Norway, Romania, Spain, and 
Sweden. 
Monitoring of shortage 
EMA’s SPOC working party2 is closely monitoring the supply 
Information for healthcare 
professionals  
situation and engaging with the marketing authorisation holder 
and other stakeholders to identify measures to mitigate the 
impact of the supply shortage.  
• 
• 
Production capacity limitations have led to intermittent 
supply shortages that are expected to continue until the 
end of 2023 in some EU Member States. 
The shortage concerns 100 and 200 units/ml solution for 
injection in pre-filled pens (FlexTouch). The cartridges of 
Tresiba solution for injection (3ml of 100 units/ml) remain 
available.  
•  Healthcare professionals should ensure that patients at risk 
of running out of Tresiba are switched to a suitable 
alternative in time. 
•  Additional advice may be available from your country’s 
national shortage register or national competent authority. 
Information for patients  
• 
Production capacity limitations have led to intermittent 
supply shortages that are expected to continue until the 
end of 2023. 
1 This information may change. For up-to-date information about the status of a medicine shortage in a particular 
Member State, contact the national competent authority. 
2 The  SPOC working party is responsible for monitoring and reporting events that could affect the supply of 
medicines in the EU. Summaries of the SPOC working party meetings can be found on EMA’s website. 
 
 
 
 
 
 
 
 
 
 
Shortage of Tresiba (insulin degludec) 
pre
filled pens (100 and 200 units/ml) 
‑
• 
• 
• 
The shortage concerns 100 and 200 units/ml solution for 
injection in pre-filled pens (FlexTouch). The cartridges of 
Tresiba solution for injection (3ml of 100 units/ml) remain 
available.  
If you are at risk of running out of Tresiba, your doctor will 
discuss with you the need to switch to a suitable 
alternative.  
If you have any questions, speak to your doctor or 
pharmacist.  
•  Additional advice may be available from your country’s 
national shortage register or national competent authority. 
Status 
Ongoing 
 
 
 
 
 
